Mast Cell Chymase Inhibits Smooth Muscle Cell Growth and Collagen Expression In Vitro
- 1 December 2001
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (12) , 1928-1933
Abstract
In the vulnerable areas of fibrous caps of advanced atherosclerotic lesions, chymase-containing mast cells are present. In such areas, the numbers of smooth muscle cells (SMCs) and the content of collagen are reduced. In this in vitro study, we found that the addition of chymase, isolated and purified from rat serosal mast cells, to cultured rat aortic SMCs of the synthetic phenotype (s-SMCs) inhibited their proliferation by blocking the G 0 /G 1 →S transition in the cell cycle. Rat chymase and recombinant human chymase inhibited the expression of collagen type I and type III mRNA in s-SMCs and in human coronary arterial SMCs. The growth-inhibitory effect of chymase was partially reversed by addition to the culture medium of an antibody capable of neutralizing the activity of transforming growth factor-β1 (TGF-β1). Immunocytochemistry showed that the s-SMCs expressed and synthesized extracellular matrix-associated TGF-β1. On exposure to mast cell chymase, the extracellular matrix-associated latent TGF-β1 was released and activated, as demonstrated by immunoblotting and by an ELISA with TGF-β1 type II receptor for capture. When added to s-SMCs, such chymase-released TGF-β1 was capable of inhibiting their growth. In contrast, the inhibitory effect of chymase on collagen synthesis by s-SMCs did not depend on TGF-β1. Taken together, the findings support the hypothesis that chymase released from activated mast cells in atherosclerotic plaques contributes to cap remodeling.Keywords
This publication has 27 references indexed in Scilit:
- Activation of paracrine TGF‐β1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymaseThe FASEB Journal, 2001
- Concordant upregulation of type II-TGF-β-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularityAtherosclerosis, 1999
- Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells.Journal of Clinical Investigation, 1997
- Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.Journal of Clinical Investigation, 1996
- Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.Journal of Clinical Investigation, 1995
- A PIVOTAL ROLE FOR TGF‐β* IN ATHEROGENESIS?Biological Reviews, 1995
- Physiological consequences of loss of plasminogen activator gene function in miceNature, 1994
- Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.Journal of Clinical Investigation, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992